Fineline Cube

Follow:
14409 Articles
Sino Biopharm's LM-350 CDH17-ADC Wins NMPA Nod for Clinical Trials
CompanyDrug

Sino Biopharm’s LM-350 CDH17-ADC Wins NMPA Nod for Clinical Trials

Cutia's CU-40105 Topical Finasteride Spray NDA Accepted by NMPA, a China First
CompanyDrug

Cutia’s CU-40105 Topical Finasteride Spray NDA Accepted by NMPA, a China First

Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine
CompanyDeals

Mirxes and Walvax Form RNA Partnership for Vaccines and Precision Medicine

NMPA Releases 98th RLD Catalog for Chemical Generics, Adding 48 New Specifications
Policy / Regulatory

NMPA Releases 98th RLD Catalog for Chemical Generics, Adding 48 New Specifications

Roche's Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma
CompanyDrug

Roche’s Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma

Roche's giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial
CompanyDrug

Roche’s giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial

Hengrui's HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial
CompanyDrug

Hengrui’s HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial

Gate Bioscience Closes $65M Series B to Advance Molecular Gates to Clinic
CompanyDeals

Gate Bioscience Closes $65M Series B to Advance Molecular Gates to Clinic

Hengrui's HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b/2 Solid Tumor Trials
CompanyDrug

Hengrui’s HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b/2 Solid Tumor Trials

Takeda Launches TCIC Digital Healthcare Innovation Center in Chengdu, a China‑First
Company

Takeda Launches TCIC Digital Healthcare Innovation Center in Chengdu, a China‑First

BeOne's Zanidatamab Achieves PFS & OS Wins in HERIZON-GEA-01 Phase 3 HER2-Positive Cancer Trial
CompanyDrug

BeOne’s Zanidatamab Achieves PFS & OS Wins in HERIZON-GEA-01 Phase 3 HER2-Positive Cancer Trial

Biokin's iza-bren ADC Achieves Dual PFS & OS Endpoints in Phase 3 Esophageal Cancer, a Global First
CompanyDrug

Biokin’s iza-bren ADC Achieves Dual PFS & OS Endpoints in Phase 3 Esophageal Cancer, a Global First